Share on StockTwits

Ultragenyx Pharmaceutical (NASDAQ:RARE) saw a significant growth in short interest in the month of July. As of July 31st, there was short interest totalling 1,695,861 shares, a growth of 33.3% from the July 15th total of 1,272,683 shares, Analyst Ratings.Net reports. Based on an average daily volume of 252,686 shares, the days-to-cover ratio is currently 6.7 days. Approximately 7.9% of the company’s stock are short sold.

Separately, analysts at Robert W. Baird initiated coverage on shares of Ultragenyx Pharmaceutical in a research note on Tuesday, July 15th. They set an “outperform” rating and a $64.00 price target on the stock. Five investment analysts have rated the stock with a buy rating, Ultragenyx Pharmaceutical has an average rating of “Buy” and a consensus target price of $74.00.

Ultragenyx Pharmaceutical (NASDAQ:RARE) opened at 53.45 on Thursday. Ultragenyx Pharmaceutical has a 52-week low of $32.02 and a 52-week high of $69.774. The stock has a 50-day moving average of $44.99 and a 200-day moving average of $45.17. The company’s market cap is $1.605 billion.

Ultragenyx Pharmaceutical (NASDAQ:RARE) last released its earnings data on Monday, August 11th. The company reported ($0.45) earnings per share for the quarter, missing the analysts’ consensus estimate of ($0.42) by $0.03. On average, analysts predict that Ultragenyx Pharmaceutical will post $-2.06 earnings per share for the current fiscal year.

Ultragenyx Pharmaceutical Inc is a development-stage biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of rare and ultra-rare diseases, with an initial focus on serious, debilitating metabolic genetic diseases.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.